Everest Medicines announced that under an amended license agreement with Spero Therapeutics, the relevant patents for SPR206 will be assigned to Everest in Greater China, South Korea and certain Southeast Asian countries. The companies announced in January 2019 a collaboration agreement to develop, manufacture and commercialize SPR206 in the Territory.